[go: up one dir, main page]

MX2014014630A - Incrementadores de linea celular de produccion. - Google Patents

Incrementadores de linea celular de produccion.

Info

Publication number
MX2014014630A
MX2014014630A MX2014014630A MX2014014630A MX2014014630A MX 2014014630 A MX2014014630 A MX 2014014630A MX 2014014630 A MX2014014630 A MX 2014014630A MX 2014014630 A MX2014014630 A MX 2014014630A MX 2014014630 A MX2014014630 A MX 2014014630A
Authority
MX
Mexico
Prior art keywords
cell
edem2
production cell
incrementers
production line
Prior art date
Application number
MX2014014630A
Other languages
English (en)
Other versions
MX360359B (es
Inventor
Gang Chen
Darya Burakov
Dipali Deshpande
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2014014630A publication Critical patent/MX2014014630A/es
Publication of MX360359B publication Critical patent/MX360359B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere al descubrimiento de la expresión ectópica de EDEM2 en una célula de producción para incrementar el rendimiento de una proteína de subunidad múltiple útil. Por lo tanto, la presente invención proporciona líneas de célula de producción, tal como la célula de producción biofarmacéutica de mamífero canónica - la célula CHO, que contiene los polinucleótidos recombinantes que codifican EDEM2. También se describe una célula de producción que contiene tanto un polinucleótido que codifica EDEM2, así como un polinucleótido que codifica XBP1. Se describen tituladores mejorados de anticuerpos producidos a través de estas líneas de células, así como las densidades de célula mejoradas logradas a través de estas células en el cultivo.
MX2014014630A 2012-05-29 2013-05-29 Incrementadores de linea celular de produccion. MX360359B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261652549P 2012-05-29 2012-05-29
PCT/US2013/043116 WO2013181253A1 (en) 2012-05-29 2013-05-29 Production cell line enhancers
US13/904,587 US9079954B2 (en) 2012-05-29 2013-05-29 Production cell line enhancers

Publications (2)

Publication Number Publication Date
MX2014014630A true MX2014014630A (es) 2015-02-12
MX360359B MX360359B (es) 2018-10-30

Family

ID=49670701

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014630A MX360359B (es) 2012-05-29 2013-05-29 Incrementadores de linea celular de produccion.

Country Status (20)

Country Link
US (9) US9079954B2 (es)
EP (3) EP4219546A3 (es)
JP (5) JP6298455B2 (es)
KR (4) KR102663134B1 (es)
CN (2) CN110835624A (es)
AU (4) AU2013267525B2 (es)
BR (1) BR112014029095A2 (es)
CA (1) CA2873131A1 (es)
DK (1) DK2875047T5 (es)
EA (2) EA201792213A1 (es)
ES (1) ES2940900T3 (es)
FI (1) FI2875047T3 (es)
HU (1) HUE061479T2 (es)
IL (4) IL320011A (es)
MX (1) MX360359B (es)
PL (1) PL2875047T3 (es)
SG (2) SG11201407652RA (es)
TW (2) TWI641687B (es)
WO (1) WO2013181253A1 (es)
ZA (1) ZA201408289B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
KR20180134894A (ko) 2016-04-20 2018-12-19 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
AU2017253241B2 (en) 2016-04-20 2024-07-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
WO2018094316A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
CN111344410B (zh) 2017-08-17 2023-09-15 济世易为生物有限公司 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
WO2003101189A1 (en) 2002-05-29 2003-12-11 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
EP1572944A4 (en) 2002-08-30 2007-12-26 Harvard College METHOD AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF XBP-1
AU2004248165A1 (en) * 2003-06-11 2004-12-23 Biogen Idec Ma Inc. Method to increase protein production in culture
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005094355A2 (en) 2004-03-31 2005-10-13 Centocor, Inc. Methods for altering protein production rates
CA2574791A1 (en) * 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
EP1784490B1 (en) * 2004-09-02 2017-11-01 Wyeth LLC Systems and methods for protein production
AU2005284798B2 (en) 2004-09-15 2012-02-02 The President And Fellows Of Harvard College Reducing ER stress in the treatment of obesity and diabetes
EP1964922A1 (en) * 2007-03-02 2008-09-03 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
WO2008115596A2 (en) 2007-03-21 2008-09-25 Danisco Us, Inc., Genencor Division Over expression of foldases and chaperones improves protein production
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
CA2693504A1 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20110281301A1 (en) * 2007-11-13 2011-11-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg The secretory capacity in host cells
US20090247609A1 (en) * 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
EP2297331B1 (en) * 2008-05-28 2015-03-25 Bayer HealthCare, LLC Methods and compositions for production of recombinant protein in hbx-expressing mammalian cells
WO2010008860A1 (en) 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
GB0902180D0 (en) 2009-02-10 2009-03-25 Ucb Pharma Sa Method for producing protein
WO2010117455A2 (en) * 2009-04-08 2010-10-14 U.S. Army Medical Research Institute Of Infectious Diseases Human monoclonal antibodies protective against bubonic plaque
KR101641526B1 (ko) 2009-06-02 2016-07-21 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JO3274B1 (ar) * 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP3919069A1 (en) 2012-11-05 2021-12-08 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions

Also Published As

Publication number Publication date
CN104350068A (zh) 2015-02-11
IL279922B2 (en) 2025-09-01
KR20150015492A (ko) 2015-02-10
AU2019203780A1 (en) 2019-06-20
BR112014029095A2 (pt) 2017-07-18
EA028790B1 (ru) 2017-12-29
IL235573B (en) 2019-09-26
JP2015518728A (ja) 2015-07-06
AU2013267525A1 (en) 2014-12-11
US20130323788A1 (en) 2013-12-05
KR102663134B1 (ko) 2024-05-03
IL279922A (en) 2021-03-01
EP2875047B1 (en) 2023-01-25
US20190270800A1 (en) 2019-09-05
ES2940900T3 (es) 2023-05-12
IL265867A (en) 2019-06-30
US9382315B2 (en) 2016-07-05
US9079954B2 (en) 2015-07-14
PL2875047T3 (pl) 2023-05-29
TWI641687B (zh) 2018-11-21
EP4219546A2 (en) 2023-08-02
CN110835624A (zh) 2020-02-25
HK1205137A1 (en) 2015-12-11
US10227401B2 (en) 2019-03-12
AU2018201094A1 (en) 2018-03-15
HUE061479T2 (hu) 2023-07-28
KR102346867B1 (ko) 2022-01-04
KR20230065370A (ko) 2023-05-11
JP7037535B2 (ja) 2022-03-16
SG11201407652RA (en) 2014-12-30
KR20220003165A (ko) 2022-01-07
AU2021240303B2 (en) 2025-02-27
EA201492242A1 (ru) 2015-05-29
CA2873131A1 (en) 2013-12-05
IL320011A (en) 2025-06-01
US9193786B2 (en) 2015-11-24
US9688751B2 (en) 2017-06-27
IL235573A0 (en) 2015-01-29
US20170291938A1 (en) 2017-10-12
USRE48651E1 (en) 2021-07-20
JP2018108094A (ja) 2018-07-12
US10611831B2 (en) 2020-04-07
AU2021240303A1 (en) 2021-10-28
JP7382383B2 (ja) 2023-11-16
KR102126210B1 (ko) 2020-06-25
CN104350068B (zh) 2019-12-03
TW201823460A (zh) 2018-07-01
KR20200074273A (ko) 2020-06-24
AU2018201094B2 (en) 2019-06-20
US20150353634A1 (en) 2015-12-10
AU2019203780B2 (en) 2021-07-01
US20150299309A1 (en) 2015-10-22
US20150299310A1 (en) 2015-10-22
EA201792213A1 (ru) 2018-01-31
JP6298455B2 (ja) 2018-03-20
EP2875047A1 (en) 2015-05-27
JP2023153268A (ja) 2023-10-17
ZA201408289B (en) 2016-09-28
EP4219546A3 (en) 2023-08-23
WO2013181253A1 (en) 2013-12-05
US10351622B2 (en) 2019-07-16
DK2875047T5 (da) 2024-10-14
JP6622334B2 (ja) 2019-12-18
JP2022044609A (ja) 2022-03-17
US20150175688A1 (en) 2015-06-25
DK2875047T3 (da) 2023-03-27
US9228012B2 (en) 2016-01-05
IL279922B1 (en) 2025-05-01
FI2875047T3 (fi) 2023-03-30
EP3564262A1 (en) 2019-11-06
KR102528950B1 (ko) 2023-05-08
US20160304598A1 (en) 2016-10-20
TW201402815A (zh) 2014-01-16
JP2020022514A (ja) 2020-02-13
MX360359B (es) 2018-10-30
SG10201606654XA (en) 2016-10-28
AU2013267525B2 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
MX2014014630A (es) Incrementadores de linea celular de produccion.
CY1123146T1 (el) Καλλιεργεια κυτταρου θηλαστικου
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
AR122864A2 (es) Variantes de lipasa y polinucleótidos que las codifican
EA201171018A1 (ru) Биореактор для культивирования клеток млекопитающих
EA201400709A1 (ru) Молекула биспецифического антитела
BR112014026308A2 (pt) composições de cultura celular e métodos para produção de polipeptídeos
CO7170149A2 (es) Producción mejorada de derivados de ácidos grasos
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
MX337985B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
MX337919B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
MX353621B (es) Variantes de alfa-amilasa.
EA201490568A1 (ru) Варианты глюкоамилазы и кодирующие их полинуклеотиды
BR112012025872A2 (pt) primidinas modificadas na posição-5 e seu uso
SG10201900948PA (en) Modified nucleotide linkers
PA8778001A1 (es) Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescencia
NZ630568A (en) Methods and means for the production of ch3 domain-comprising molecules
AR096270A1 (es) Composiciones detergentes
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
IN2014CN00597A (es)
EA201490649A1 (ru) Варианты глюкоамилазы и кодирующие их полинуклеотиды
MX337913B (es) Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican los mismos.
BR112015009774A2 (pt) polipeptídeos citocromo p450 e citocromo p450 redutase, codificando moléculas de ácido nucléicos e usos das mesmas
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.

Legal Events

Date Code Title Description
FG Grant or registration